Cutler Group’s Heron Therapeutics HRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $7K | Sell |
2,800
-100
| -3% | -$251 | ﹤0.01% | 1432 |
|
|
2023
Q4 | $4K | Hold |
2,900
| – | – | ﹤0.01% | 2832 |
|
|
2023
Q3 | $2K | Hold |
2,900
| – | – | ﹤0.01% | 3267 |
|
|
2023
Q2 | $3K | Hold |
2,900
| – | – | ﹤0.01% | 2856 |
|
|
2023
Q1 | $4K | Hold |
2,900
| – | – | ﹤0.01% | 2833 |
|
|
2022
Q4 | $7K | Hold |
2,900
| – | – | ﹤0.01% | 2940 |
|
|
2022
Q3 | $12K | Sell |
2,900
-436
| -13% | -$1.71K | ﹤0.01% | 2985 |
|
|
2022
Q2 | $9K | Sell |
3,336
-1,600
| -32% | -$6.42K | ﹤0.01% | 3274 |
|
|
2022
Q1 | $28K | Buy |
4,936
+2,036
| +70% | +$14.9K | ﹤0.01% | 2761 |
|
|
2021
Q4 | $26K | Hold |
2,900
| – | – | ﹤0.01% | 2916 |
|
|
2021
Q3 | $31K | Hold |
2,900
| – | – | ﹤0.01% | 2942 |
|
|
2021
Q2 | $45K | Buy |
2,900
+1,100
| +61% | +$17.5K | ﹤0.01% | 2568 |
|
|
2021
Q1 | $29K | Buy |
1,800
+1,700
| +1,700% | +$30.3K | ﹤0.01% | 2866 |
|
|
2020
Q4 | $2K | Sell |
100
-7,149
| -99% | -$124K | ﹤0.01% | 4168 |
|
|
2020
Q3 | $107K | Buy |
7,249
+2,749
| +61% | +$42.9K | 0.01% | 1273 |
|
|
2020
Q2 | $66K | Sell |
4,500
-2,900
| -39% | -$47.6K | ﹤0.01% | 1568 |
|
|
2020
Q1 | $86K | Buy |
+7,400
| New | +$139K | ﹤0.01% | 1399 |
|
|
2019
Q4 | – | Sell |
-4,500
| Closed | -$83K | – | 4232 |
|
|
2019
Q3 | $83K | Buy |
4,500
+1,600
| +55% | +$29.4K | 0.01% | 1184 |
|
|
2019
Q2 | $53K | Buy |
2,900
+2,300
| +383% | +$45.9K | ﹤0.01% | 1504 |
|
|
2019
Q1 | $14K | Sell |
600
-100
| -14% | -$2.62K | ﹤0.01% | 2273 |
|
|
2018
Q4 | $18K | Sell |
700
-300
| -30% | -$8.25K | ﹤0.01% | 2173 |
|
|
2018
Q3 | $31K | Buy |
1,000
+700
| +233% | +$26.1K | ﹤0.01% | 1938 |
|
|
2018
Q2 | $11K | Sell |
300
-11,043
| -97% | -$352K | ﹤0.01% | 2605 |
|
|
2018
Q1 | $313K | Buy |
+11,343
| New | +$257K | 0.03% | 595 |
|
|
2017
Q4 | – | Sell |
-3,816
| Closed | -$62.2K | – | 5295 |
|
|
2017
Q3 | $61K | Sell |
3,816
-14,334
| -79% | -$225K | ﹤0.01% | 2058 |
|
|
2017
Q2 | $251K | Buy |
18,150
+13,759
| +313% | +$199K | 0.01% | 1110 |
|
|
2017
Q1 | $65K | Sell |
4,391
-52,091
| -92% | -$721K | ﹤0.01% | 2125 |
|
|
2016
Q4 | $739K | Buy |
56,482
+32,623
| +137% | +$512K | 0.03% | 519 |
|
|
2016
Q3 | $411K | Buy |
23,859
+13,614
| +133% | +$253K | 0.02% | 709 |
|
|
2016
Q2 | $184K | Sell |
10,245
-6,797
| -40% | -$133K | 0.01% | 1173 |
|
|
2016
Q1 | $323K | Buy |
17,042
+9,975
| +141% | +$197K | 0.02% | 727 |
|
|
2015
Q4 | $188K | Buy |
+7,067
| New | +$189K | 0.01% | 1230 |
|
Other funds holding HRTX
RCMNY
O
VCIM
TC
PCM
Cutler Group's HRTX Position: Q1 2024 in Review
Cutler Group reduced its Heron Therapeutics (HRTX) stake by 3.4% in Q1 2024, selling an estimated $251 and leaving 2,800 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #1432.
Cutler Group first reported a position in HRTX in Q4 2015 and has held it in 32 quarters since. The position peaked at $739K in Q4 2016. 161 funds tracked by Wall St. Rank hold HRTX as of Q1 2024.
- Cutler Group held 2,800 shares of Heron Therapeutics worth $7K as of Q1 2024.
- Cutler Group sold 100 Heron Therapeutics shares in Q1 2024, an estimated $251.
- Heron Therapeutics made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1432 holding.
- Cutler Group first reported a position in Heron Therapeutics in Q4 2015 and has held it in 32 quarters since.
- Cutler Group's Heron Therapeutics position peaked at $739K in Q4 2016.
- 161 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2024.
Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.